Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals


  • Products Id :- GDPH0477MD
  • |
  • Pages: 104
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for March 2015 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include-North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons To Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 9

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2015 12

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2015 14

2.2.1 AbbVie to Acquire Pharmacyclics for USD21 Billion 14

2.2.2 Actavis Raises USD21 Billion in Public Offering of Senior Notes 15

2.2.3 UnitedHealth to Acquire Catamaran for USD12.8 Billion 15

2.2.4 Valeant Pharma Raises USD10.1 Billion in Private Placement of Senior Notes 15

2.2.5 Teva Pharma to Acquire Auspex Pharma for USD3.2 Billion 16

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2015 17

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2015 18

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 19

3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2015 19

3.1.1 Top M&A Deals in March 2015 20

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2014-March 2015 21

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2015 23

3.2.1 Top Equity Offering Deals in March 2015 24

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2014-March 2015 25

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2015 27

3.3.1 Top PE/VC Deals in March 2015 28

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2015 29

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2015 30

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, October 2014-March 2015 32

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2014-March 2015 33

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2015 34

4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2015 34

4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2014-March 2015 36

4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (USD m), March 2015 38

4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2015 39

4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 40

4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2014-March 2015 42

4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (USD m), October 2014-March 2015 43

4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), October 2014-March 2015 45

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2015 47

5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2015 47

5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), March 2015 49

5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (USD m), October 2014-March 2015 51

5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (USD m), October 2014-March 2015 53

5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (USD m), October 2014-March 2015 55

5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (USD m), October 2014-March 2015 58

5.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2015 59

5.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2015 60

5.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2015 61

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 62

6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2015 62

6.1.1 Oncology-Deals of the Month 63

6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2015 65

6.2.1 Central Nervous System-Deals of the Month 66

6.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2015 68

6.3.1 Infectious Diseases-Deals of the Month 69

6.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2015 71

6.4.1 Cardiovascular-Deals of the Month 72

6.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2015 74

6.5.1 Immunology-Deal of the Month 75

6.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, March 2015 77

6.6.1 Gastrointestinal-Deals of the Month 78

6.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2015 80

6.7.1 Metabolic Disorders-Deal of the Month 81

7 Deal Summary by Geography 83

7.1 Pharmaceuticals & Healthcare, North America Deals, March 2015 83

7.1.1 North America-Deals of the Month 84

7.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2015 87

7.2.1 Europe-Deals of the Month 88

7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2015 91

7.3.1 Asia-Pacific-Deals of the Month 92

7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2015 94

7.4.1 Rest of the World-Deals of the Month 95

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 97

8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2014-March 2015 97

8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2014-March 2015 99

9 Further Information 101

9.1 Methodology 101

9.2 About GlobalData 102

9.3 Disclosure information 103

9.4 Disclaimer 103

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (USD m), October 2014-March 2015 12

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2015 17

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2015 18

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (USD m), October 2014-March 2015 19

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, October 2014-March 2015 21

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (USD m), October 2014-March 2015 23

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (USD m), October 2014-March 2015 25

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (USD m), October 2014-March 2015 27

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (USD m), by Therapy Area, October 2014-March 2015 29

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2015 30

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2015 31

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), October 2014-March 2015 32

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), October 2014-March 2015 34

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), October 2014-March 2015 36

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 38

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 40

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014-March 2015 42

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014-March 2015 43

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (USD m), October 2014-March 2015 45

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (USD m), October 2014-March 2015 47

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 49

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), October 2014-March 2015 51

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 53

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2014-March 2015 55

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (USD m), October 2014-March 2015 56

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (USD m), March 2015 58

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (USD m), October 2014-March 2015 62

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (USD m), October 2014-March 2015 65

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (USD m), October 2014-March 2015 68

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (USD m), October 2014-March 2015 71

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (USD m), October 2014-March 2015 74

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 77

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 80

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (USD m), October 2014-March 2015 83

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (USD m), October 2014-March 2015 87

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (USD m), October 2014-March 2015 91

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (USD m), October 2014-March 2015 94

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), October 2014-March 2015 97

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), October 2014-March 2015 99

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 13

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2015 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2015 18

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 20

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2015 20

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (USD m), by Therapy Area, October 2014-March 2015 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 24

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2015 24

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 26

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 28

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2015 28

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2014-March 2015 29

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2015 31

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (USD m), October 2014-March 2015 32

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2014-March 2015 33

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (USD m), October 2014-March 2015 35

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (USD m), October 2014-March 2015 37

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 39

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (USD m), March 2015 39

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 41

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014-March 2015 44

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (USD m), October 2014-March 2015 46

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 48

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (USD m), October 2014-March 2015 50

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (USD m), October 2014-March 2015 52

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (USD m), March 2015 54

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2014-March 2015 57

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (USD m), March 2015 59

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2015 59

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2015 60

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2015 61

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 63

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 66

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 69

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 72

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 75

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 78

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 81

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 84

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 88

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 92

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (USD m), October 2014-March 2015 95

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (USD m), October 2014-March 2015 98

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (USD m), October 2014-March 2015 100

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

select a license

Single User License
USD 1000 INR 64940
Site License
USD 2000 INR 129880
Corporate User License
USD 3000 INR 194820

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com